Peringatan Keamanan

Symptoms of overdose include vomiting, unconsciousness, and severe low blood pressure.

Moricizine

DB00680

small molecule approved investigational withdrawn

Deskripsi

An antiarrhythmia agent used primarily for ventricular rhythm disturbances.

Struktur Molekul 2D

Berat 427.517
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) 2 hours (range 1.5-3.5 hours).
Volume Distribusi * 300 L
Klirens (Clearance) -

Absorpsi

Well absorbed, absorption is complete within 2 to 3 hours. Significant first-pass metabolism results in an absolute bioavailability of approximately 38%. Administration within 30 minutes after a meal slows the rate, but does not affect the extent of absorption, although peak plasma concentrations are reduced.

Metabolisme

Hepatic and extensive, to at least 26 metabolites, none accounting for as much as 1% of the administered dose. Two metabolites may be pharmacologically active but are present in extremely small quantities. Moricizine induces its own metabolism (it induces hepatic cytochrome P-450 activity).

Rute Eliminasi

Less than 1% of orally administered Ethmozine® is excreted unchanged in the urine. Approximately 56% of the administered dose is excreted in the feces and 39% is excreted in the urine.

Interaksi Obat

1120 Data
Buprenorphine Moricizine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
Doxylamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Moricizine.
Dronabinol Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Moricizine.
Droperidol Droperidol may increase the central nervous system depressant (CNS depressant) activities of Moricizine.
Hydrocodone Moricizine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
Magnesium sulfate The therapeutic efficacy of Moricizine can be increased when used in combination with Magnesium sulfate.
Methotrimeprazine Moricizine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.
Minocycline Minocycline may increase the central nervous system depressant (CNS depressant) activities of Moricizine.
Mirtazapine Moricizine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
Nabilone Nabilone may increase the central nervous system depressant (CNS depressant) activities of Moricizine.
Orphenadrine Moricizine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
Paraldehyde Moricizine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
Perampanel Perampanel may increase the central nervous system depressant (CNS depressant) activities of Moricizine.
Pramipexole Moricizine may increase the sedative activities of Pramipexole.
Ropinirole Moricizine may increase the sedative activities of Ropinirole.
Rotigotine Moricizine may increase the sedative activities of Rotigotine.
Rufinamide The risk or severity of adverse effects can be increased when Rufinamide is combined with Moricizine.
Sodium oxybate Moricizine may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.
Suvorexant Moricizine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
Tapentadol Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Moricizine.
Thalidomide Moricizine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
Zolpidem Moricizine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
Amisulpride Moricizine may increase the antipsychotic activities of Amisulpride.
Methylphenidate The risk or severity of adverse effects can be increased when Moricizine is combined with Methylphenidate.
Dexmethylphenidate The risk or severity of adverse effects can be increased when Moricizine is combined with Dexmethylphenidate.
Metoclopramide The risk or severity of adverse effects can be increased when Metoclopramide is combined with Moricizine.
Quinagolide The therapeutic efficacy of Quinagolide can be decreased when used in combination with Moricizine.
Sulpiride Moricizine may increase the antipsychotic activities of Sulpiride.
Methadone The risk or severity of adverse effects can be increased when Methadone is combined with Moricizine.
Lithium citrate Lithium citrate may increase the neurotoxic activities of Moricizine.
Lithium hydroxide Lithium hydroxide may increase the neurotoxic activities of Moricizine.
Mequitazine Moricizine may increase the arrhythmogenic activities of Mequitazine.
Tetrabenazine The risk or severity of adverse effects can be increased when Moricizine is combined with Tetrabenazine.
Deutetrabenazine The risk or severity of adverse effects can be increased when Moricizine is combined with Deutetrabenazine.
Thiopental The risk or severity of adverse effects can be increased when Moricizine is combined with Thiopental.
Metyrosine The risk or severity of extrapyramidal symptoms and CNS depression can be increased when Metyrosine is combined with Moricizine.
Ethanol Moricizine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
Azelastine Moricizine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
Brimonidine Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Moricizine.
Fluvoxamine The risk or severity of adverse effects can be increased when Moricizine is combined with Fluvoxamine.
Duloxetine The risk or severity of adverse effects can be increased when Moricizine is combined with Duloxetine.
Paroxetine The risk or severity of adverse effects can be increased when Moricizine is combined with Paroxetine.
Sertraline The risk or severity of adverse effects can be increased when Moricizine is combined with Sertraline.
Sibutramine The risk or severity of adverse effects can be increased when Moricizine is combined with Sibutramine.
Nefazodone The risk or severity of adverse effects can be increased when Moricizine is combined with Nefazodone.
Zimelidine The risk or severity of adverse effects can be increased when Moricizine is combined with Zimelidine.
Dapoxetine The risk or severity of adverse effects can be increased when Moricizine is combined with Dapoxetine.
Milnacipran The risk or severity of adverse effects can be increased when Moricizine is combined with Milnacipran.
Desvenlafaxine The risk or severity of adverse effects can be increased when Moricizine is combined with Desvenlafaxine.
Seproxetine The risk or severity of adverse effects can be increased when Moricizine is combined with Seproxetine.
Levomilnacipran The risk or severity of adverse effects can be increased when Levomilnacipran is combined with Moricizine.
Indalpine The risk or severity of adverse effects can be increased when Moricizine is combined with Indalpine.
Ritanserin The risk or severity of adverse effects can be increased when Moricizine is combined with Ritanserin.
Alaproclate The risk or severity of adverse effects can be increased when Moricizine is combined with Alaproclate.
Citalopram The risk or severity of QTc prolongation can be increased when Moricizine is combined with Citalopram.
Escitalopram The risk or severity of adverse effects can be increased when Moricizine is combined with Escitalopram.
Labetalol The serum concentration of Labetalol can be increased when it is combined with Moricizine.
Pindolol The serum concentration of Pindolol can be increased when it is combined with Moricizine.
Bevantolol The serum concentration of Bevantolol can be increased when it is combined with Moricizine.
Penbutolol The serum concentration of Penbutolol can be increased when it is combined with Moricizine.
Bufuralol The serum concentration of Bufuralol can be increased when it is combined with Moricizine.
Bopindolol The serum concentration of Bopindolol can be increased when it is combined with Moricizine.
Arotinolol The serum concentration of Arotinolol can be increased when it is combined with Moricizine.
Levobetaxolol The serum concentration of Levobetaxolol can be increased when it is combined with Moricizine.
Bucindolol The serum concentration of Bucindolol can be increased when it is combined with Moricizine.
Esatenolol The serum concentration of Esatenolol can be increased when it is combined with Moricizine.
Cloranolol The serum concentration of Cloranolol can be increased when it is combined with Moricizine.
Mepindolol The serum concentration of Mepindolol can be increased when it is combined with Moricizine.
Epanolol The serum concentration of Epanolol can be increased when it is combined with Moricizine.
Morphine The risk or severity of hypotension and CNS depression can be increased when Moricizine is combined with Morphine.
Codeine The risk or severity of hypotension and CNS depression can be increased when Moricizine is combined with Codeine.
Hydromorphone The risk or severity of hypotension and CNS depression can be increased when Moricizine is combined with Hydromorphone.
Meperidine The risk or severity of hypotension and CNS depression can be increased when Moricizine is combined with Meperidine.
Oxycodone The risk or severity of hypotension and CNS depression can be increased when Moricizine is combined with Oxycodone.
Butorphanol The risk or severity of hypotension and CNS depression can be increased when Moricizine is combined with Butorphanol.
Dextropropoxyphene The risk or severity of hypotension and CNS depression can be increased when Moricizine is combined with Dextropropoxyphene.
Pentazocine The risk or severity of hypotension and CNS depression can be increased when Moricizine is combined with Pentazocine.
Naltrexone The risk or severity of hypotension and CNS depression can be increased when Moricizine is combined with Naltrexone.
Sufentanil The risk or severity of hypotension and CNS depression can be increased when Moricizine is combined with Sufentanil.
Alfentanil The risk or severity of hypotension and CNS depression can be increased when Moricizine is combined with Alfentanil.
Fentanyl The risk or severity of hypotension and CNS depression can be increased when Moricizine is combined with Fentanyl.
Nalbuphine The risk or severity of hypotension and CNS depression can be increased when Moricizine is combined with Nalbuphine.
Levorphanol The risk or severity of hypotension and CNS depression can be increased when Moricizine is combined with Levorphanol.
Remifentanil The risk or severity of hypotension and CNS depression can be increased when Moricizine is combined with Remifentanil.
Diphenoxylate The risk or severity of hypotension and CNS depression can be increased when Moricizine is combined with Diphenoxylate.
Oxymorphone The risk or severity of hypotension and CNS depression can be increased when Moricizine is combined with Oxymorphone.
Dezocine The risk or severity of hypotension and CNS depression can be increased when Moricizine is combined with Dezocine.
Levacetylmethadol The risk or severity of hypotension and CNS depression can be increased when Moricizine is combined with Levacetylmethadol.
Methadyl acetate The risk or severity of hypotension and CNS depression can be increased when Moricizine is combined with Methadyl acetate.
Dihydroetorphine The risk or severity of hypotension and CNS depression can be increased when Moricizine is combined with Dihydroetorphine.
Diamorphine The risk or severity of hypotension and CNS depression can be increased when Moricizine is combined with Diamorphine.
Bezitramide The risk or severity of hypotension and CNS depression can be increased when Moricizine is combined with Bezitramide.
Ethylmorphine The risk or severity of hypotension and CNS depression can be increased when Moricizine is combined with Ethylmorphine.
Etorphine The risk or severity of hypotension and CNS depression can be increased when Moricizine is combined with Etorphine.
Dextromoramide The risk or severity of hypotension and CNS depression can be increased when Moricizine is combined with Dextromoramide.
Desomorphine The risk or severity of hypotension and CNS depression can be increased when Moricizine is combined with Desomorphine.
Carfentanil The risk or severity of hypotension and CNS depression can be increased when Moricizine is combined with Carfentanil.
Dihydrocodeine The risk or severity of hypotension and CNS depression can be increased when Moricizine is combined with Dihydrocodeine.
Alphacetylmethadol The risk or severity of hypotension and CNS depression can be increased when Moricizine is combined with Alphacetylmethadol.
Dihydromorphine The risk or severity of hypotension and CNS depression can be increased when Moricizine is combined with Dihydromorphine.

Target Protein

Sodium channel protein type 5 subunit alpha SCN5A

Referensi & Sumber

Belum ada data referensi/link/attachment untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field referensi.

Contoh Produk & Brand

Produk: 3 • International brands: 1
Produk
  • Ethmozine
    Tablet • 200 mg/1 • Oral • US • Approved
  • Ethmozine
    Tablet • 250 mg/1 • Oral • US • Approved
  • Ethmozine
    Tablet • 300 mg/1 • Oral • US • Approved
International Brands
  • Etmozins — Olainfarm

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul